DIHUA YU to Trastuzumab
This is a "connection" page, showing publications DIHUA YU has written about Trastuzumab.
Connection Strength
0.601
-
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Res. 2017 10 01; 77(19):5374-5383.
Score: 0.119
-
Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Res. 2014 May; 24(5):542-59.
Score: 0.094
-
Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res. 2012 Sep 01; 72(17):4417-28.
Score: 0.084
-
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 2011 Apr; 17(4):461-9.
Score: 0.076
-
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010 Oct; 177(4):1647-56.
Score: 0.074
-
Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol. 2001 Oct; 28(5 Suppl 16):12-7.
Score: 0.040
-
Role of erbB2 in breast cancer chemosensitivity. Bioessays. 2000 Jul; 22(7):673-80.
Score: 0.036
-
MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Sci Signal. 2014 Jul 29; 7(336):ra71.
Score: 0.024
-
The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 2012 May 25; 149(5):1098-111.
Score: 0.021
-
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011 Aug 10; 29(23):3126-32.
Score: 0.020
-
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006 May; 3(5):269-80.
Score: 0.014